Dr. Aaron Kesselheim, MD

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Pennsylvania Perelman School Of Medicine

  Medical School, 2002

• Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021 Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2023-01-25

• Ensuring Medical Device Effectiveness and Safety: A Cross - National Comparison of Approaches to Regulation, 2014-05-30

• The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs, 2012-02-21

• Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments, 2022-08-16

• Review times and adverse events for cardiovascular devices, 2017-01-10

• Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D, 2023-02-24

• Persistence of resistance: a panel data analysis of the effect of antibiotic usage on the prevalence of resistance, 2023-02-28

• Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use, 2023-07-06

• Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021 Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021, 2023-03-31

• Mitigating bias in machine learning for medicine, 2021-08-23

• Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020 Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020, 2023-04-07

• Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval, 2016-10-21

• The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?, 2016-02-09

• Public Approval of Exception From Informed Consent in Emergency Clinical Trials A Systematic Review of Community Consultation Surveys Public Approval of Exception From Informed Consent in Emergency Clinical Trials, 2019-07-24

• Same Song, Different Audience: Pharmaceutical Promotion Targeting Non-Physician Health Care Providers, 2013-11-26

• Getting the Right Evidence After Drug Approval, 2020-09-09

• The next forum for unraveling FDA off-label marketing rules: State and federal legislatures, 2018-05-08

• Prescription Drug Insurance Coverage and Patient Health Outcomes: A Systematic Review, 2015-02-26

• Rising Health Care Costs and Life-Cycle Management in the Pharmaceutical Market, 2013-06-04

• Ethical and Legal Views Regarding Deactivation of Cardiac Implantable Electrical Devices in Patients With Hypertrophic Cardiomyopathy, 2011-02-04

• A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors A Meta-analysis of Correlation and Differences in Effect Sizes Differences in Overall vs Progression-Free Survival Following Treatment With PD-1 Inhibitors, 2018-06-22

• Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021 Advisory Committee Votes and US Food and Drug Administration Decisions on Prescription Drugs, 2023-07-07

• Seizure Outcomes Following Use of Generic vs. Brand-Name Antiepileptic Drugs: A Systematic Review and Meta-Analysis, 2010-03-26

• The ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment, 2010-07-19

• Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis, 2016-03-31

• Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States, 2015-03-17

• Therapeutic Value of Drugs Frequently Marketed Using Direct-to-Consumer Television Advertising, 2015 to 2021 Therapeutic Value of Drugs Marketed Using Direct-to-Consumer Television Advertising, 2023-01-13

• Paying tissue donors: The legacy of Henrietta Lacks, 2012-07-06

• Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints, 2011-04-05

• Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration, 2022-04-19

• Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019 Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019, 2022-04-06

• Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs, 2021-05-04

• Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis, 2020-09-29

• Association of Medical Students' Reports of Interactions with the Pharmaceutical and Medical Device Industries and Medical School Policies and Characteristics: A Cross-Sectional Study, 2014-10-14

• Uptake of the First Biosimilar Infliximab since its Approval in South Korea, 2016-01-31

• Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021 Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization, 2022-08-19

• Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage, 2017-01-03

• International reference pricing for prescription drugs: a landscape analysis, 2021-09-01

• Medicare Spending on Drugs With Accelerated Approval, 2015-2019 Medicare Spending on Drugs With Accelerated Approval, 2015-2019, 2021-12-03

• Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures, 2023-03-06

• Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019 Medicaid and Non-Medicaid Net Prices of Brand-name Drugs With Best Price Rebates, 2015 to 2019, 2023-01-13

• An Uninformative Truth: The Logic of Amarin's Off-Label Promotion, 2016-03-15

• Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use Experiences and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use, 2022-01-20

• Medical Students' Exposure to and Attitudes about the Pharmaceutical Industry: A Systematic Review, 2011-05-24

• Postmarket Surveillance of Medical Devices: A Comparison of Strategies in the US, EU, Japan, and China, 2013-09-24

• Differences in Diabetic Prescription Drug Utilization and Costs Among Patients With Diabetes Enrolled in Colorado Marketplace and Medicaid Plans, 2014-2015 Diabetic Prescription Drug Utilization and Costs in Colorado Marketplace and Medicaid Plans, 2022-01-14

• Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs A Systematic Review and Pooled Analysis Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Cancer Drug Trials, 2019-08-30

• Competition and price among brand-name drugs in the same class: A systematic review of the evidence, 2019-07-30

• Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures, 2012-08-07

• Coverage of Magnetic Resonance Imaging for Patients With Cardiac Devices Improving the Coverage With Evidence Development Program, 2017-07-01

• Anticipated efficiencies, real costs: Medicaid managed care organizations and the pharmacy benefit, 2022-03-01

• How Does Medical Device Regulation Perform in the United States and the European Union? A Systematic Review, 2012-07-31

• Insulin Access and Affordability in the US: Anticipating the First Interchangeable Insulin Product, 2020-03-20

• Reporting bias in clinical trials: Progress toward transparency and next steps, 2022-01-19

• Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020 Characteristics of Postmarketing Studies for FDA-Approved Vaccines, 2006-2020, 2021-04-30

• Approval of High-Risk Medical Devices in the US: Implications for Clinical Cardiology, 2014-05-30

• Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes A Systematic Review and Meta-analysis Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes, 2019-04-12

• FDA Policy and Cardiovascular Medicine, 2015-09-22

• Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997, 2021-01-04

• Prescribing systemic steroids for acute respiratory tract infections in United States outpatient settings: A nationwide population-based cohort study, 2020-03-31

• The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine, 2017-04-07

• Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020 Supportive Evidence for FDA Approvals of Novel Drugs in 2020, 2022-05-17

• Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval, 2021-02-22

• Clinicians' Contributions to the Development of Coronary Artery Stents: A Qualitative Study of Transformative Device Innovation, 2014-02-12

• Desmopressin and the risk of hyponatremia: A population-based cohort study, 2019-10-21

• Drug Product Life-Cycle Management as Anticompetitive Behavior: The Case of Memantine, 2016-04-01

• Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims, 2019-03-13

• Patents and regulatory exclusivities on inhalers for asthma and COPD, 1986-2020, 2022-05-17